에 대한 최신 뉴스 Abbott Laboratories (NYSE:ABT) 주식

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

News

Markets

General

콜럼버스 데이가 다가오면서 투자자들과 시장 참가자들은 독특한 거래 환경에 대비하고 있다. 이 미국 공휴일은 2024년 10월 14일 월요일에 관찰되며, 금융 시장이 열리고 닫히는 혼합 상태로 거래 활동에 영향을 미칠 것이다.

콜럼버스 데이: 오늘 주식시장이 열리나요?

Earnings

Equities

Pre-Market Outlook

Trading Ideas

NFLX

목요일 아침 (동부 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월스트리트는 D.R. 호튼(NYSE:DHI)이 개장 전 매출 97억 7천만 달러, 주당 3.77달러의 분기 이익을 보고할 예정이다. 벤징가 프로의 데이터에 따르면 D.R. 호튼의 주식은 시간외 거래에서 0.3% 상승한 158.00달러를 기록했다.

목요일 주목해야 주식: D.R. 호튼, 노바티스, 넷플릭스 그리고  2종목

ETFs

ADRT

ARGT

BSAC

DFEN

DXYZ

GOLD

JCPB

NUSI

UPRO

XPER

뉴욕 증권 거래소(NYSE)의 여러 주식들은 기술적 문제로 인해 월요일 동부 표준시 오전 9시 40분 이후 갑자기 거래가 중단되었다. 이번 예상치 못한 거래 중단은 일반적으로 단일 주식의 과도한 변동성을 억제하는 데 사용되는 &#34;상향 한도(Limit Up)/하향 한도(Limit Down)&#34; 코드로 분류된 기술적 문제로 인해 촉발되었다.

버크셔 해서웨이, 치폴레 등 뉴욕 증권 거래소 기술적 문제로 일시 거래 중단 발생

Arcblock - United States dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

Alberta Government Adds Abbott Laboratories' Freestyle Libre 2 Flash Glucose Monitoring System To Alberta Drug Benefit List

Abbott Reports Completion Of In-human Leadless Left Bundle Branch Area Pacing  Procedures Using Investigational AVEIR CSP Leadless Pacemaker System

<ul>
<li>Dividend increased by 7.3%</li>
<li>Quarterly dividend payout has increased more than 60% since 2020</li>
<li>404th consecutive quarterly dividend to be paid by Abbott since 1924</li>
</ul>
ABBOTT PARK, Ill., Dec. 13, 2024 /PRNewswire/ -- Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) today announced that its board of directors has increased the company's quarterly common dividend to 59 cents per share, an increase of 7.3%. The company's quarterly dividend&nbsp;payout has increased more than 60% since 2020.

Dividends

Abbott Increases Quarterly Dividend From $0.55 To $0.59 Per Share

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) is one of his <a href="https://www.benzinga.com/quote/OXY/analyst-ratings">&#8220;least favorite oils.&#8221;</a>
On Monday, UBS analyst Josh Silverstein maintained Occidental Petroleum with a Neutral and lowered the price target from&nbsp;$58&nbsp;to&nbsp;$51, while Wells Fargo analyst Roger Read maintained the stock with an Equal-Weight and cut the price target from&nbsp;$56&nbsp;to&nbsp;$53.
&#8220;I think it's a very good situation,&#8221; Cramer said when asked about The Cooper Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COO#NYSE">COO</a>).
<ul>
<li><a href="https://analytics.google.com/analytics/web/#/p283071105/reports/explorer?params=_u..nav%3Dmaui%26_r..dataFilters%3D%5B%7B%22type%22:1,%22fieldName%22:%22landingPage%22,%22evaluationType%22:4,%22expressionList%22:%5B%22%252Ftrading-ideas%252Flong-ideas%252F24%252F04%252F38312296%252Fjim-cramer-recommends-buying-ethereum-or-bitcoin-instead-of-this-stock-lets-not-fool-aro%22%5D,%22complement%22:false,%22isCaseSensitive%22:true,%22expression%22:%22%22%7D%5D&amp;r=6342961161&amp;ruid=all-pages-and-screens,life-cycle,engagement&amp;collectionId=6114769606" target="_blank" rel="noreferrer noopener"></a></li>
</ul>
See Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38312296/jim-cramer-recommends-buying-ethereum-or-bitcoin-instead-of-this-stock-lets-not-fool-aro">Jim Cramer Recommends Buying Ethereum Or Bitcoin Instead Of This Stock: &#8216;Let&#8217;s Not Fool Around</a>
Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) is the &#8220;ultimate speculative, and as long as you know that, then I'm absolutely fine with it,&#8221; Cramer said.
Cramer recommended to keep owning Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) and also recommended buying more in case it goes down.
The Mad Money host said he likes Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>). &#8220;I think that their legal stuff is really largely behind them,&#8221; he added.
When asked about Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>), he said, &#8220;It's a good situation.&#8221;
As for Advanced Drainage Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>), the company &#8220;missed the numbers by a mile,&#8221; Cramer said. &#8220;And when I see that, that often means that the next numbers' going to be missed too. So let's be careful there.&#8221;
Price Action:
<ul>
<li>Occidental Petroleum shares fell 0.9% to settle at $48.05 on Tuesday.</li>
<li>Cooper Companies shares fell 0.2% to close at $99.08.</li>
<li>Energy Transfer shares slipped 0.5% to settle at $18.74 on Tuesday.</li>
<li>Abbott shares gained 0.5% to $115.50 on Tuesday.</li>
<li>Kinder Morgan shares fell 0.8% to close at $26.89 on Tuesday.</li>
<li>Advanced Drainage Systems shares fell 1.7% to settle at $128.24 during the session.</li>
<li>Archer Aviation shares slipped 1.3% to close at $7.72 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42429201/dow-falls-for-4th-straight-session-alphabet-surges-on-google-quantum-chip-announcement-fear-greed-index-remains-in-neutral-zone">Dow Falls For 4th Straight Session, Alphabet Surges On Google Quantum Chip Announcement: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

ACHR

Jim Cramer Says 'Keep Owning' This Energy Stock, Abbott Laboratories 'Legal Stuff' Is Behind Them

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has fallen 14.63% since its last report. The company recently reported that it has 12.05 million shares sold short, which is 0.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733495423_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.06%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Abbott Laboratories's Recent Short Interest

Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating&nbsp;symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided balloon-expandable TAVI system&nbsp;and is designed to build a foundation for artificial intelligence (AI) guided procedures. Once the investigational balloon-expandable system completes clinical development and is approved by regulatory authorities, Abbott's structural heart portfolio will offer physicians another TAVI management option to meet the patient's&nbsp;needs along with the company's Navitor&#x2122; TAVI system, which is already commercially available.
The aortic valve is a heart valve that controls the flow of oxygen-rich blood to the body. With age, calcium may build up in the valve and cause it to narrow – a condition known as aortic stenosis – resulting in the heart needing to work harder to pump blood through the valve. Left untreated, aortic stenosis can cause symptoms, such as chest pain, shortness of breath and fainting, and it can weaken the heart and become life-threatening. Patients who are at risk of open-heart surgery due to age, frailty or having multiple other conditions may benefit from minimally invasive treatment options where a device is delivered to the heart through an artery in the leg. Aortic stenosis remains the most common primary valve disease and its prevalence increases with age, ranging from approximately 2% in adults 70-80 years of age to 9% in adults older than 80 years.1
The investigational system is a type of balloon-expandable TAVI device, which works by crimping the new heart valve on a deflated balloon. The balloon with the mounted valve is then inserted into the body through an artery in the groin and routed up to the heart. Once properly positioned inside the narrowed heart valve, the balloon is inflated to expand the new valve, taking over the function of the patient's narrow native heart valve. The balloon is then deflated and removed from the body.

Abbott Tests New Balloon-Expandable TAVI System for Aortic Stenosis, Launches First Patient Procedures With Investigational TAVI Device

Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) (Insulet or the Company), the global leader in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54155373&amp;newsitemid=20241120268759&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=807c8b95f30f75f117e9943595c99975">tubeless insulin pump</a> technology with its Omnipod&#xAE; brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S.

PODD

Insulet Announces Omnipod 5 System Is Now Compatible With Abbott's FreeStyle Libre 2 Plus Sensor In The U.S.

<a href="https://abbott.mediaroom.com/press-releases?item=124678" title="https://abbott.mediaroom.com/press-releases?item=124678">https://abbott.mediaroom.com/press-releases?item=124678</a>

Biotech

Abbott's Amplatzer Amulet Device Demonstrates Superior Long-Term Stroke Prevention And Reduced Blood-Thinner Use In AFib Patients Compared To Watchman; Five-Year Data Presented At AHA 2024 And Published In JACC

The global plant-based Active Pharmaceutical Ingredient (API) market is projected to grow at a steady pace, reaching a valuation of $52.1 billion by 2034, according to a <a href="https://www.futuremarketinsights.com/reports/plant-based-api-market">new report</a> by Future Market Insights. The industry is expected to expand at a Compound Annual Growth Rate (CAGR) of 5.6%, fueled by rising demand for natural and sustainable pharmaceutical solutions, including <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a> and <a href="https://www.benzinga.com/topic/cannabis-products">cannabis-derived</a> compounds.
<h3 class="wp-block-heading">Rising Demand For Psychedelic And Cannabis-Based Ingredients</h3>
A significant driver of market growth is the increasing use of psychoactive and plant-derived substances in modern pharmacology. Psychedelics like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and cannabinoids such as <a href="https://www.benzinga.com/topic/cbd">CBD</a> and <a href="http://v">THC</a> are gaining attention for their <a href="http://v">therapeutic potential</a> in mental health and oncology. The U.S., a key player in the market, is leveraging biotechnological advances like <a href="https://www.genome.gov/genetics-glossary/CRISPR#:~:text=CRISPR%20(short%20for%20%E2%80%9Cclustered%20regularly,editing%20systems%20found%20in%20bacteria.">CRISPR</a> and synthetic biology to scale production of these high-demand APIs, contributing to a 4.2% CAGR.
"The global shift toward sustainable, plant-based solutions reflects both consumer interest in natural medicine and the pharmaceutical industry's focus on alternative therapies," said Sabyasachi Ghosh, associate VP at Future Market Insights. The market&#8217;s rapid expansion underscores the increasing acceptance of psychedelics and cannabis as mainstream pharmaceutical ingredients.
<h3 class="wp-block-heading">Therapeutic Applications And Key Botanical Sources</h3>
Plant-based APIs are harnessed from well-documented medicinal plants such as cannabis, ginseng, turmeric and cinchona. These natural sources contain bioactive compounds like flavonoids, terpenes and alkaloids, offering various therapeutic benefits. Major applications of plant-based APIs include pain management, anti-inflammatory treatments and oncology therapies.
The incorporation of cannabinoids, particularly CBD and THC, into pharmaceutical formulations is reshaping the landscape of pain and anxiety treatments. Similarly, psychoactive compounds from plants like Syrian rue and Psilocybe mushrooms are being explored for treating mental health disorders like depression and PTSD.
<h3 class="wp-block-heading">Regional Growth And Market Segmentation</h3>
The report highlights robust growth in Asian markets, with India leading at an 8.8% CAGR, followed closely by China (8.7%) and South Korea (8.6%). These regions are investing heavily in agricultural biotechnologies and expanding their capabilities in plant-based pharmaceutical production.
The market segments by product type, covering alkaloids, cannabinoids, <a href="https://www.benzinga.com/markets/cannabis/24/05/39064102/cannabis-terpenes-alleviate-chemo-induced-neuropathic-pain-study-shows-added-benefits-with-morph">terpenes</a>, flavonoids and polyphenols. It also includes API forms like extracts, powders and resins from botanicals such as opium poppy, turmeric, ginseng and cannabis.
<h3 class="wp-block-heading">Competitive Landscape: Psychedelics And Cannabis Companies Lead the Charge</h3>
The plant-based API sector is experiencing intense competition, particularly in the cannabis and psychedelics segments. Companies are rapidly scaling production and forming key partnerships to meet the rising demand for plant-based, pharmaceutical-grade ingredients.
Recent developments include Bright Green Corporation's agreement to supply <a href="https://www.benzinga.com/24/02/37292778/dea-clears-this-nasdaq-traded-plant-touching-firm-to-research-and-produce-schedule-i-and-ii-plant-ba">DEA-approved marijuana</a> extracts and psychedelic compounds to Benuvia Operations. Indena's authorization from Italian regulators to produce pharmaceutical-grade CBD further illustrates the expanding global footprint of cannabis-derived APIs.
Key players in the industry include the Illinois-based Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), New Mexico&#8217;s Bright Green Corporation, Indena S.p.A., headquartered in Milan, Italy, Alchem International Pvt. Ltd., based in India, Israeli Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>); Roquette Frères, based in Lestrem, France; and Sami-Sabinsa Group, based in New Jersey.
<h3 class="wp-block-heading">The Future Of Plant-Based APIs: Sustainable And Psychedelic Solutions</h3>
The growing demand for sustainable, natural treatments will likely position the plant-based API market at the forefront of global healthcare. As pharmaceutical companies continue to explore the therapeutic potential of bioactive compounds from plants, the integration of psychedelics and cannabis-derived APIs is likely to play a pivotal role in shaping the next decade of medicine.
Cover image made with AI

Cannabis

Market Summary

Psychedelics

Global

TEVA

Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids

In the last three months, 15 analysts have published ratings on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $129.93, a high estimate of $149.00, and a low estimate of $117.00. This upward trend is evident, with the current average reflecting a 4.91% increase from the previous average price target of $123.85.
<img src="https://www.benzinga.com/files/images/story/2024/1730818870_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Abbott Laboratories among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$138.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$146.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>David Lewis</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$117.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$129.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$131.00</td>
<td>-</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$119.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Abbott Laboratories. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Abbott Laboratories's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Abbott Laboratories's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>Discovering Abbott Laboratories: A Closer Look</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Financial Insights: Abbott Laboratories</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Abbott Laboratories displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 4.85%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Abbott Laboratories's net margin is impressive, surpassing industry averages. With a net margin of 15.48%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.16%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.23%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Abbott Laboratories adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Ratings For Abbott Laboratories

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $143 to $149.

Price Target

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $149

Reducing Need For Repeat Procedures By 48% Compared To Balloon Angioplasty; New Data From LIFE-BTK Trial Presented At VIVA 2024
<a href="https://abbott.mediaroom.com/press-releases?item=124676" title="https://abbott.mediaroom.com/press-releases?item=124676">https://abbott.mediaroom.com/press-releases?item=124676</a>

Abbott's Esprit BTK System Shows Sustained Two-Year Benefits For Treating Severe Peripheral Artery Disease Below The Knee

WIIM

Abbott Laboratories shares are trading higher after the company announced it along with Reckitt Benckiser won its first trial in premature-infant formula litigation and is cleared of allegations of hiding bowel disease risks.

Abbott Laboratories and a unit of Reckitt Benckiser Group Plc were cleared by a jury over claims they hid risks their premature-infant formulas can cause a bowel disease that severely sickened a baby boy. It was the companies' first trial win in litigation over the products.
<a href="https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial" title="https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial">https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial</a>

RBGLY

Reported October 31: Abbott Laboratories And Reckitt Benckiser Win First Trial In Premature-Infant Formula Litigation, Cleared Of Allegations Of Hiding Bowel Disease Risks

<ul>
<li>The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure
<ul>
<li>Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner in their disease progression</li>
</ul>
</li>
</ul>

Abbott Initiates First-Of-Its0Kind Clinical Trial To Improve Outcomes Patients With Advanced Heart Failure

In the current market session, Abbott Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) stock price is at $116.19, after a 0.68% decrease. However, over the past month, the company's stock increased by 2.51%, and in the past year, by 24.17%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1729618243_0.png" alt="Past Year Chart" />

<h3>Abbott Laboratories P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Abbott Laboratories has a lower P/E than the aggregate P/E of 265.82 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729618243_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Abbott Laboratories

Shares of surgical tool and medical instrument stocks are trading higher in sympathy with Intuitive Surgical, which gained on strong Q3 earnings.

On Wednesday,&nbsp;Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.55 billion</a>.
Organic sales growth for the underlying base business was 8.2%, led by double-digit&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41356487/abbott-laboratories-q3-earnings-revenue-and-eps-beat-company-says-well-positioned-to-achieve-upper-" rel="noreferrer noopener">growth in Medical Devices</a>. Abbott&#8217;s adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20.
Abbott projects full-year 2024 adjusted EPS of $4.64-$4.70 versus&nbsp;<a target="_blank" href="https://www.benzinga.com/24/07/39839507/abbott-laboratories-q2-earnings-revenue-and-profit-beat-estimates-nudges-up-annual-profit-guidance-o" rel="noreferrer noopener">prior guidance of $4.61-$4.71</a> and consensus of $4.66. It forecasts fourth-quarter adjusted EPS of $1.31-$1.37 versus the consensus of $1.20.
William Blair anticipates that Abbott will return to a more typical pattern of double-digit earnings growth in the fourth quarter, a trend that is expected to continue into 2025 as the company moves past the impacts of the &#8220;COVID-cloud&#8221; management mentioned earlier.
Looking ahead to 2025, the analyst writes that Abbott has built a robust pipeline of products poised to drive a high-single-digit growth rate, an acceleration compared to pre-COVID levels.
William Blair notes that the investment landscape remains attractive, particularly given Abbott&#8217;s valuation compared to other large-cap MedTech peers experiencing similar growth.
The analyst anticipates a potential upside in EPS if macroeconomic headwinds diminish in the coming quarters, viewing 2024 as a transitional year leading to a resurgence in low-double-digit earnings growth by 2025.
Given that the stock is currently trading at 22.8 times William Blair&#8217;s 2025 EPS estimate of $5.16, the analyst maintains an <a href="https://www.benzinga.com/quote/ABT/analyst-ratings" target="_blank" rel="noreferrer noopener">Outperform rating on Abbott</a>.
<h2 class="wp-block-heading">Abbott Laboratories Stock Prediction For 2024</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Abbott Laboratories, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Abbott Laboratories, the 200-day moving average sits at $110.38, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is below the current price of $117.31. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: ABT stock is down 0.22% at $117.56 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41385280/universal-stainless-finds-new-home-as-luxembourg-based-aperam-makes-big-us-move-details" target="_blank" rel="noreferrer noopener">Universal Stainless Finds New Home As Luxembourg-Based Aperam Makes Big US Move: Details</a>.</li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Health Care

Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic

There are many reasons to own Abbott Laboratories (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>), but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the 11th top-returning stock since 1937 and #1 among healthcare names.&nbsp;
The critical takeaways from the report are time and consistency: the top performers produce slower annual growth than flash-in-the-pan growth stories but do it year in and year out, compounding value over the long term. Value is driven by company growth, cash flow, and capital returns, which, in Abbott&#39;s case, include dividends and share repurchases. Abbott stock can also help reduce portfolio risk because its low beta is about 0.7x the S&amp;P 500.
<h2>High-Quality Abbott Stock: Corporate Growth That Pays You to Own It</h2>
Abbott Laboratories had a solid Q3, reporting 4.9% growth to outpace the consensus forecast despite the impact of lower COVID-related sales and discontinued business. Organically, ongoing business grew by 8.2% due to strength in the medical device segment. Medical Devices grew by 11.7% reported and 13.3% organic due to a double-digit increase in Structural Heart and Heart Failure and the release of continuous glucose monitors, showing the strength of the diversified portfolio.&nbsp;
Regarding the remaining segments, established Pharmaceuticals grew by 2.7% on a reported basis and 7% organically, offset by reported declines in Nutrition and Diagnostics. Nutrition contracted by 0.3% as reported but grew by 3.4% organically, while Diagnostics declined by 1.3% on a reported basis but grew by 1.4% organically.&nbsp;
Margin news is also solid, sustaining the outlook for balance sheet health and capital returns. The company&#39;s operating and net margin widened slightly compared to the previous year, driving earnings leverage. The operating and net operating earnings are up 12.8% and 14.6%, leaving the adjusted fully diluted EPS at $1.21 or up 6%, with margins forecasted to remain stable in Q4.&nbsp;
Abbott&#39;s guidance is favorable in that revenue targets were reaffirmed, and the mid-point for earnings was raised. The company expects full-year earnings in a range centering on $4.67 versus the $4.66 consensus, which should keep the analysts happy and support the uptrend in share prices.&nbsp;
<h2>Abbott Laboratories Capital Return Grows Safely, Drives Value for Shareholders</h2>
Abbott Laboratories&#39; capital return is safe and reliable, with a 53-year history of sustained annual increases and a low payout ratio below 50%. The balance sheet is a fortress with no red flags, leaving ample cash flow for R&amp;D, reinvestment, acquisitional cash flow, and share repurchases. Repurchase activity isn&#39;t robust but sufficient to offset dilutive forces and reduce the count annually. Highlights from Q3 include a 0.05% YTD share count reduction and a freshly amended repurchase authorization worth $7 billion or about 3.5% of the market cap before the release.&nbsp;&nbsp;
Analysts&#39; support for Abbott is strong. The trend in calendar Q3 is increasing coverage, improving sentiment, and upward price target revisions. The consensus is a Moderate Buy verging on a Strong Buy with a price target of $125, about 10% above the post-release opening price. The freshest revisions lead to the high-end range, another 10% to 15% above the consensus target, and a new all-time high when reached.
<h2>Abbott Slips Into a Buying Opportunity</h2>
The price action following the release was tepid, with share prices pulling back slightly. However, analysts and institutions support the market well, so the pullback should result in a buying signal soon. The critical support target is near $115 and will likely be tested. If the market can sustain support above that level, a move to fresh highs is likely before the year&#39;s end. If not, Abbott Laboratories&#39; share price may remain range-bound until more is available.&nbsp;
<img alt="Abbott Laboratories ABT stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241016081501_chart-abt-10162024.png" style="height:448px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/abbotts-growth-and-dividends-make-it-a-smart-portfolio-pick/">Abbott&#39;s Growth and Dividends Make It a Smart Portfolio Pick</a>&quot; first appeared on MarketBeat.

Large Cap

Guidance

Technicals

Abbott's Growth and Dividends Make It a Smart Portfolio Pick

Bernstein analyst Lee Hambright maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $133 to $138.

Bernstein Maintains Outperform on Abbott Laboratories, Raises Price Target to $138

Dividend Champion, Contender, And Challenger Highlights: Week Of December 15

Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value

Mairs & Power Balanced Fund Q3 2024 Commentary

The medtech market is thriving, thanks to the increasing investments and surging demand for enhanced efficiency. Therefore, investors could benefit from these trends by investing in fundamentally solid medical device stocks Becton, Dickinson and Company (BDX), Medtronic (MDT), and Abbott Laboratories (ABT), which are revolutionizing patient care. Keep reading... Patient care is changing globally due to the increasing aging population and the rising prevalence of chronic diseases, which results in higher demand for personalized medicine and the latest technologies. Following this, the global medtech market is continuously transforming with the rapid adoption of technological advancements like AI and ML.
Amid this backdrop, fundamentally sound medtech stocks Becton, Dickinson and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>), Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>), and Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>) could be ideal portfolio additions as they revolutionize patient care.
In recent times, technology has been a key driver of medical innovations, offering enhanced outcomes, lower costs, and improved access to better patient care. Also, amid the rising complications, global rise in diseases, and demand for personalized medicines, the involvement of technology is becoming more and more integral.
With this evolving landscape, industry leaders are pouring in investments to accelerate <a href="https://www.startus-insights.com/innovators-guide/medical-devices-market-report/#:~:text=In%202025%2C%20the%20medical%20devices,simulations%20will%20reshape%20healthcare%20delivery.">the adoption of innovative medical devices</a> to enhance diagnostics, treatment, and monitoring capabilities. In the upcoming year as well, key trends, including surgical robotics, 3D simulations, and brain-implanting technologies, will reshape patient care.
Statista projects the worldwide medical technology market to reach a staggering $597 billion in 2024, whereas the medical devices market is expected to dominate and reach $508 billion in 2024. The market is further anticipated to witness significant revenue growth in the coming years, <a href="https://www.statista.com/outlook/hmo/medical-technology/worldwide">growing at a CAGR of 5.3%</a>, resulting in a market volume of $772.50 billion by 2029.
Further, with advanced algorithms, machine learning techniques, and other technologies, artificial intelligence (AI) is enhancing the medical devices market. With this, <a href="https://www.thebusinessresearchcompany.com/report/ai-in-medical-devices-global-market-report">AI in the medical devices market</a> is expected to reach $97.07 billion in 2028, at a CAGR of 44.4%, driven by rising demand for personalized medicine, remote healthcare services, and the emergence of wearable devices.
Considering these conducive industry trends, let's analyze the fundamentals of the three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> stocks mentioned above, beginning with the third choice.
Stock #3: Becton, Dickinson, and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>)
BDX develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public globally. It operates in three segments: BD Medical; BD Life Sciences; and BD Interventional.
On October 30, BDX launched the new BD&#xAE; Intraosseous Vascular Access System, which allows access to rapid delivery of fluids or medication in critical emergency circumstances. The procedure involves inserting a needle into the bone marrow cavity when intravenous (IV) access is challenging or delayed.
On October 14, BDX launched a new robotics solution that can automate and standardize single-cell research. This first in a family of high-throughput, robotics-compatible reagent kits allows automation to ensure higher consistency and increased efficiency of large-scale, single-cell discovery studies.
The automation will standardize traditionally manual processes and help accelerate lab work leading to Genomic sequencing.
During the fourth quarter that ended on September 30, 2024, BDX's revenues increased 6.9% year-over-year to $5.44 billion. Its <a href="https://www.investopedia.com/terms/o/operatingincome.asp">operating income</a> grew 86.4% from the year-ago value to $650 million. The company's net income applicable to common shareholders of $421 million indicates growth of 290.1% from the prior year's quarter.
In addition, the company's adjusted EPS from continuing operations came in at $3.81, up 11.4% year-over-year, respectively.
Analysts expect BDX's revenue for the first quarter (ending December 2024) to grow 8.8% year-over-year to $5.12 billion. The company's EPS is expected to increase 11.7% year-over-year to $2.99 for the ongoing period. Furthermore, the company surpassed the consensus EPS estimates in each of the trailing four quarters.
BDX's shares have declined 4.7% over the past month to close the last trading session at $223.01.
BDX's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Growth, Sentiment, and Stability. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, BDX is ranked #33 out of 138 stocks.
<a href="https://stocknews.com/stock/BDX/">Click here</a> to access additional BDX ratings for Value, Momentum, and Quality.
Stock #2: Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>)
MDT develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients globally. The company operates through Cardiovascular Portfolio; Neuroscience Portfolio; Medical Surgical Portfolio; and Diabetes Operating Unit segments.
On November 20, MDT announced U.S. FDA clearance for its new InPen&#x2122; app, having features like the detection of missed meal doses, paving the way for its Smart MDI system launch with the Simplera&#x2122; continuous glucose monitor (CGM). MDT's Smart MDI system brings together its InPen&#x2122; smart insulin pen and newest Simplera&#x2122; CGM.
After clearance, the system became the first to recommend corrections for missed or inaccurate insulin doses, providing real-time, personalized insights for individuals on multiple daily injection therapies.
Also, on November 1, MDT was granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral&#x2122; renal denervation (RDN) catheter by the Centers for Medicare &amp; Medicaid Services (CMS). RDN is used in the Symplicity&#x2122; blood pressure procedure under the Medicare Hospital Outpatient Prospective Payment System.
TPT payment supports patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.
MDT's net sales increased 5.2% year-over-year to $8.40 billion for the second quarter, which ended October 25, 2024. Its non-GAAP operating profit grew 1.6% from the year-ago value to $2.04 billion. Net income attributable to Medtronic and EPS came in at $1.27 billion and $0.99, up 39.7% and 45.6% from the prior year's quarter, respectively.
The company has again raised its fiscal year 2025 guidance from the prior range, increasing its organic revenue growth projection to 4.75% to 5%. It also raised its adjusted non-GAAP EPS guidance to $5.44 to $5.50 from the prior range of $5.42 to $5.50. This revised guidance suggests a 4.6% to 5.8% growth in non-GAAP EPS.
Street expects MDT's revenue for the third quarter (ending January 2025) to increase 3% year-over-year to $8.33 billion, and its EPS is expected to grow 4.6% year-over-year to $1.36 for the same period. Moreover, the company surpassed the consensus revenue and EPS estimates in all of the trailing four quarters, which is impressive.
MDT's stock has increased 1% over the past six months and 5.3% over the past year to close the last trading session at $83.96.
MDT's sound fundamentals are reflected in its POWR Ratings. It has an overall rating of B, translating to a Buy in our proprietary rating system.
The stock has a B grade for Stability and Value. Within the same industry, MDT is ranked #26 out of 138 stocks.
In addition to the POWR Ratings we've stated above, we also have MDT ratings for Growth, Momentum, Sentiment, and Quality. Get all MDT ratings <a href="https://stocknews.com/stock/MDT/">here</a>.
Stock #1: Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>)
ABT discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through four segments: Established Pharmaceutical Products; Diagnostic Products; Nutritional Products; and Medical Devices.
On October 10, ABT achieved new major milestones to support its pulsed field ablation (PFA) solutions suite in electrophysiology. ABT completed enrollment ahead of schedule in the global VOLT-AF IDE study supporting the Volt&#x2122; PFA System and launched the FOCALFLEX trial to assess its TactiFlex&#x2122; Duo Ablation Catheter, Sensor Enabled&#x2122; (SE) for treating paroxysmal atrial fibrillation.
Also, the company announced U.S. FDA clearance of its Advisor&#x2122; HD Grid X Mapping Catheter, Sensor Enabled&#x2122;, to support mapping of both PFA and radiofrequency (RF) ablation cases, where visualization of cardiac anatomy is critical. It ensures the best outcomes for people undergoing ablation procedures.
For the third quarter, which ended on September 30, 2024, ABT's net sales increased by 4.9% year-over-year to $10.64 billion. Its operating earnings of $1.86 billion reflect a growth of 12.8% from the prior year's quarter. Also, the company's adjusted net earnings stood at $2.12 billion or $1.21 per common share, indicating increases of 5.9% and 6.1% year-over-year, respectively.
Street expects ABT's revenue and EPS for the fourth quarter (ending December 2024) to increase 7.8% and 12.8% year-over-year to $11.04 billion and $1.34, respectively. Also, the company has topped the consensus EPS and revenue estimates in all four trailing quarters, which is remarkable.
Shares of ABT have surged 6.9% over the past six months and 8.2% over the past year to close the last trading session at $114.90.
ABT's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
ABT has a B grade for Stability and Sentiment. It is ranked #13 out of 138 stocks in the Medical – Devices &amp; Equipment industry.
In addition to the POWR Ratings stated above, we also have ABT ratings for Quality, Growth, Momentum, and Value. Get all ABT ratings <a href="https://stocknews.com/stock/ABT/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ABT shares were trading at $115.58 per share on Tuesday afternoon, up $0.68 (+0.59%). Year-to-date, ABT has gained 7.10%, versus a 28.26% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/abt-mdt-bdx-3-medtech-innovators-revolutionizing-patient-care/>3 MedTech Innovators Revolutionizing Patient Care</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 MedTech Innovators Revolutionizing Patient Care

The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical technology. Hence, investors might consider investing in healthcare stocks, Eli Lilly (LLY), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) for a healthy portfolio in 2025. Read more… The increase in the number of elderly people, faster economic growth, technological advancements, changes in lifestyles, and enhanced ability to survive and standard of living are expected to contribute to the growth of the healthcare services Market.
Given this backdrop, it could be wise to consider investing in fundamentally strong healthcare stocks, Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>), Thermo Fisher Scientific Inc. (<a href="https://stocknews.com/stock/TMO/">TMO</a>), and Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>) for a healthy portfolio in 2025.
The healthcare industry is experiencing significant growth, driven by rapid technological advancements that enhance efficiency and accessibility, as well as a surge in partnerships fostering innovation and the development of solutions.
Ongoing progress in pharmaceuticals and medical technologies continues to propel the sector forward, with global pharmaceutical revenues expected to hit $1.16 trillion this year and grow at a <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">CAGR of 6.2%</a>, reaching $1.47 trillion by 2028.
Diagnostics also plays a crucial role, which is why the global clinical diagnostics market is worth $86.72 billion in 2024 and is projected to <a href="https://www.biospace.com/clinical-diagnostics-market-size-to-hit-usd-140-53-billion-by-2033">expand at a CAGR of 5.5%</a> by 2033.
Given these favorable industry trends, let's look at the fundamentals of three healthcare stocks.
Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>)
LLY discovers, develops, and markets human pharmaceuticals worldwide. The company offers medicines for diabetes, obesity, and other cardiometabolisms.
On December 5, 2024, LLY announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing facility that the company acquired earlier this year.
This investment would extend the company's global parenteral (injectable) product manufacturing network, helping meet the growing demand for diabetes, obesity, and future pipeline medicines across therapeutic areas.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp">EBITDA margin</a>, LLY's 40.54% is 626.1% higher than the 5.58% industry average. Likewise, its 11.34% trailing-12-month CAPEX/ Sales is 260.6% higher than the 3.14% industry average. Its 36.46% trailing-12-month EBIT margin is considerably higher than the 2.54% industry average.
During the third quarter ended September 30, 2024, LLY's revenue increased by 20% year-over-year to $11.44 billion. The company's non-GAAP net income was $1.06 billion, or $1.18 per share, up considerably year-over-year.
The consensus revenue estimate of $14 billion for the fiscal fourth quarter (ending December 2024) represents a 49.7% increase year-over-year. The company expects its EPS to increase 118.5% year-over-year to $5.44. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in three of the trailing four quarters.
Over the past year, the stock has surged 34.4%, closing the last trading session at $803.58.
LLY's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
LLY has a B grade for Sentiment and Growth. It is ranked #30 out of 155 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/LLY/">Click here</a> to see the additional ratings for LLY (Value, Momentum, Quality, and Stability).
Thermo Fisher Scientific Inc. (<a href="https://stocknews.com/stock/TMO/">TMO</a>)
TMO is engaged in helping life sciences research, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies globally. It operates through four segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services.
On November 12, 2024, TMO announced a collaborative agreement with Mainz Biomed N.V. (<a href="https://stocknews.com/stock/MYNZ/">MYNZ</a>), a molecular genetics diagnostic company specializing in early cancer detection.
The collaboration agreement would enable MYNZ and TMO to jointly develop and potentially commercialize Mainz Biomed's Next Generation colorectal cancer screening product. 
In terms of the trailing-12-month levered FCF margin, TMO's 16.01% is 610.6% higher than the 2.25% industry average. Its 0.43x trailing-12-month asset turnover ratio is 4.4% higher than the 0.41x industry average. Similarly, the stock's 17.42% trailing-12-month EBIT margin is 595.5% higher than the 2.51% industry average.
For the third quarter of 2024, which ended on September 28, 2024, TMO's revenue increased marginally year-over-year to $10.60 billion. Its adjusted net income for the quarter amounted to $2.03 billion, while its adjusted EPS stood at $5.28.
Street expects TMO's revenue and EPS for the fiscal fourth quarter (ending December 2024) to increase 3.8% and 5% year-over-year to $11.30 billion and $4.95, respectively. Moreover, it beat the revenue estimates in each of the trailing four quarters, which is promising.
Shares of TMO have gained 9.7% over the past year to close the last trading session at $537.23.
TMO's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
TMO has a B grade for Sentiment and Stability. It is ranked #4 out of 41 stocks in the <a href="https://stocknews.com/category/medical-diagnostics-research/">Medical - Diagnostics/Research</a> industry.
In addition to the POWR Ratings we've stated above, we also have TMO ratings for Momentum, Growth, Value, and Quality. Get all TMO ratings <a href="https://stocknews.com/stock/TMO/">here</a>.
Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>)
ABT discovers, develops, manufactures, and sells healthcare products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
On November 25, 2024, ABT announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward ABT's software-guided balloon-expandable TAVI system and is designed to build a foundation for AI-guided procedures. 
In terms of the trailing-12-month levered FCF margin, ABT's 15.54% is 589.8% higher than the 2.25% industry average. Its 0.56x trailing-12-month asset turnover ratio is 36.9% higher than the 0.41x industry average. Similarly, the stock's 18.44% trailing-12-month EBIT margin is 636.2% higher than the 2.51% industry average.
For the third quarter that ended on September 30, 2024, ABT's net sales rose 4.9% year-over-year to $20.34 billion. Its operating earnings grew 12.8% from the year-ago value to $1.86 billion. In addition, the company's adjusted net earnings stood at $2.12 billion, or $0.94 per share.
The consensus revenue estimate of $11.04 billion for the fiscal fourth quarter (ending December 2024) represents a 7.8% increase year-over-year. The consensus EPS estimate of $1.34 for the same quarter indicates a 12.8% improvement year-over-year. The company has an impressive earnings surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Over the past six months, the stock has surged 6.8%, closing the last trading session at $114.90.
ABT's POWR Ratings reflect its bright outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. 
ABT has a B grade for Stability and Sentiment. It is ranked #13 out of 138 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. <a href="https://stocknews.com/stock/ABT/">Click here</a> to see the additional ratings for ABT (Growth, Value, Momentum, and Quality).
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
LLY shares were trading at $801.78 per share on Tuesday afternoon, down $1.80 (-0.22%). Year-to-date, LLY has gained 38.44%, versus a 28.32% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/lly-tmo-abt-mynz-3-healthcare-stocks-to-buy-now-for-a-healthy-portfolio/>3 Healthcare Stocks to Buy Now for a Healthy Portfolio in 2025</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks to Buy Now for a Healthy Portfolio in 2025

Least shorted S&P 500 stocks in November

This is why you should turn defensive, underweight cyclicals – UBS

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price tar...

Abbott Laboratories (ABT) Gets a Buy from Piper Sandler

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veru (VERU – Research Report), Ascendis Pharma (ASND...

Analysts Are Bullish on These Healthcare Stocks: Veru (VERU), Ascendis Pharma (ASND)

Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline

AAPL

ABBV

ADBE

ALLE

AMGN

AMZN

APLO

ASND

AVGO

BAESF

BCPC

BKNG

BSVN

CABO

CARR

CASY

CBSH

CCBG

CHRW

CINF

CMCSA

COST

CSCO

CSGS

CTVA

DSMFF

ENSG

ENTG

EONGY

EPRT

ERIE

EVRG

EXPO

FRME

GOLF

GOOG

GOOGL

INVH

ISRG

JJSF

JKHY

KFRC

KLIC

LAND

LFUS

MBWM

MDLZ

MHVYF

MSFT

MYNZ

NDAQ

NEOG

NRIM

NVDA

ODFL

OFLX

OLED

ORCL

OTEX

PRGO

QCOM

QDEF

RBCAA

SAMG

SBUX

SEIC

SWBI

SYIEF

TCBK

TECH

TELNF

TMUS

TSCDF

TSLA

TTWO

UBCP

UBER

VCTR

VERU

VICI

WDFC

Screenshot 2024-12-03 at 7.43.04 PM

DXCM

GCTK

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Screenshot 2024-10-03 at 5.30.47 PM

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Press Releases

New Canadian Report Shows Positivity Instead of Criticism is Key in Diabetes Management

Comments

Abbott Laboratories

뉴스

에 대한 최신 뉴스 Abbott Laboratories (NYSE:ABT) 주식

월요일, 10월 14, 2024

목요일, 7월 18, 2024

화요일, 6월 04, 2024

수요일, 4월 17, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌